Welcome to our dedicated page for Disc Medicine SEC filings (Ticker: IRON), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Disc Medicine filings document the regulatory and financial record of a clinical-stage biopharmaceutical company developing hematologic disease therapies. Its Form 8-K disclosures cover quarterly and annual financial results, corporate updates, clinical-program materials for bitopertin, DISC-0974 and DISC-3405, and FDA communications related to the bitopertin New Drug Application for erythropoietic protoporphyria.
The filing record also includes proxy materials covering board matters, executive compensation and shareholder voting items. Material-event reports describe Regulation FD presentations, operating runway disclosures, restructuring actions following regulatory developments, and risk-related statements around clinical trials, regulatory pathways, research spending and capital resources.
Disc Medicine, Inc. (IRON) has a notice from company officer Kevin J. Bitterman indicating an intention to sell up to 27,136 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney, with an aggregate market value of about $1,902,504.96.
The shares relate to an exercise of options under a registered plan for cash on September 11, 2026. Common shares outstanding are listed as 38,392,844, as context for the potential sale.
Disc Medicine, Inc. (IRON) reported initial Phase 2 RESTORE-PV trial results for its investigational anti-TMPRSS6 antibody DISC-3405 in adults with polycythemia vera. The 40‑patient, multi-center, open-label study includes two cohorts receiving 300 mg subcutaneous dosing every 2 weeks (Cohort A) or every 4 weeks (Cohort B) after dose escalation.
In Cohort A, pharmacodynamic data showed dose-proportional exposure, increased hepcidin, reduced serum iron, and increased ferritin, with mean hematocrit maintained below 45% through week 26 and initial improvement in symptom burden. Among 13 Cohort A patients completing 26 weeks, mean total phlebotomy events fell from 4.0 to 0.6 over 26 weeks (p<0.0001), with 61.5% remaining phlebotomy-free; 77.8% of those completing weeks 12–32 were phlebotomy-free in that period.
Across Cohorts A and B, DISC-3405 was generally described as well-tolerated, with adverse events consistent with underlying disease and mild, self-limited injection site reactions. Disc plans to provide a further RESTORE-PV update and initial Phase 1b DISC-3405 sickle cell disease data, and to share FDA feedback and pivotal plans for selcodebart in anemia of myelofibrosis, by the end of 2026.
Disc Medicine, Inc. (IRON) reported that director Kevin Bitterman, through venture funds with which he is associated, reported sales totaling 1,689 shares of common stock on September 4, 2026 at a weighted average price of $79.96 per share.
The sales were made pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026. The 912-share block was sold by Atlas Venture Opportunity Fund I, L.P., the 759-share block by Atlas Venture Opportunity Fund II, L.P., and the 18-share block by Atlas Venture Fund XII, L.P.; Bitterman disclaims beneficial ownership of these securities except to the extent of any pecuniary interest.
Disc Medicine, Inc. (IRON) received a Rule 144 notice covering a small planned resale of its common stock by Atlas Venture Fund XII. The filing reports that 18 shares of common stock may be sold through Merrill Lynch, with an aggregate market value of $1,428.66, on or about September 4, 2026, on Nasdaq.
The shares were originally acquired in a Private Placement from the issuer for cash on May 1, 2020. The notice also refers to an attached schedule describing additional sales over the prior three months.
Disc Medicine, Inc. (IRON) has a notice of proposed sale under Rule 144 filed on behalf of Atlas Venture Opportunity Fund II for up to 759 shares of common stock. The shares were originally acquired from the issuer in a private placement on May 1, 2020 for cash.
The filing lists an aggregate market value of $60,241.83 for the shares covered by this notice and references 38,392,844 shares of common stock outstanding as of September 4, 2026 as contextual share information.
Disc Medicine, Inc. (IRON) received a notice that Atlas Venture Opportunity Fund I plans to sell 912 shares of its common stock under Rule 144 through Merrill Lynch. The shares were acquired in a private placement from the issuer on May 1, 2020 for cash.
The planned sale has an aggregate market value of $72,385.44. As context, 38,392,844 shares of Disc Medicine common stock were outstanding as of September 4, 2026; this is a baseline figure, not the amount being offered.
Disc Medicine, Inc. (IRON) received a notice that Atlas Venture Fund X intends to sell common stock under Rule 144. The notice covers 2,212 shares of common stock of Disc Medicine with an indicated aggregate market value of $175,566.44, to be sold through Merrill Lynch on or after September 4, 2026 on Nasdaq.
The selling holder reports owning these 2,212 shares from a May 1, 2020 private placement by the issuer for cash. The notice also refers to additional sales over the prior three months in an attached table not included here.
Disc Medicine, Inc. (IRON) reported that funds affiliated with director Kevin Bitterman sold an aggregate of 54,496 shares of Common Stock in open‑market transactions from September 1–3, 2026 at weighted average prices around $80 per share, pursuant to a Rule 10b5-1 trading plan adopted on July 30, 2026.
The shares were sold indirectly through Atlas Venture Opportunity Fund I, L.P., Atlas Venture Opportunity Fund II, L.P., and Atlas Venture Fund XII, L.P.; Bitterman is a member of entities that serve as their general partners and disclaims beneficial ownership of the securities held by these funds except to the extent of his pecuniary interest, if any.
Disc Medicine, Inc. (IRON) received a notice of proposed sale of restricted shares under Rule 144 by Atlas Venture Fund XII. The filing covers 54 shares of Common Stock, originally acquired in a private placement on May 1, 2020, with the shares listed on Nasdaq.
Disc Medicine, Inc. (IRON) received a notice that Atlas Venture Opportunity Fund II plans to sell common stock under Rule 144. The notice covers 2,339 shares of common stock, with an aggregate market value of $187,236.95, to be sold through Merrill Lynch on or after September 3, 2026 on Nasdaq. Disc Medicine had 38,392,844 shares of common stock outstanding as of the same date; this is a baseline figure, not the amount being sold. The shares to be sold were originally acquired in a private placement on May 1, 2020 for cash.